HALO BIOSCIENCES INC
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $3.0Mattributed |
|---|---|
| Latest round | grant, $3.0M, 2024-01-01attributed |
| Founded | unknown |
| Headquarters | PALO ALTO, California |
| Industry | unknown |
| Stage | unknown |
| Website | halobiosciences.com |
Halo Biosciences develops disease-modifying drugs that target hyaluronan-mediated extracellular-matrix remodelling, with H1614 as lead candidate. Indications include Group 3 pulmonary hypertension, interstitial lung disease, pulmonary fibrosis, and liver fibrosis. The mechanism is positioned as first- and best-in-class for ECM-driven inflammation and fibrosis.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-01-01 | grant | $3.0M | undisclosed |
Detected tech stack
GoDaddy Website Builder 8.0.0000, PayPal, Vercel Speed Insights, React
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $3.0M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $3.0M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | halobiosciences.com, read 2026-05-02 |
| Description | self-reported | halobiosciences.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.